News
-
Swiss start-up Akroswiss has announced that it raised “several million Swiss Franc” for development of the company’s midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include… Read more . . .
-
DPI developer Iconovo has announced that its development deal with Amneal for a generic version of Symbicort has been amended to add US and Chinese marketing rights for Amneal and Nordic region marketing rights for… Read more . . .
-
Liquidia has announced the resubmission of its NDA for LIQ861 dry powder treprostinil for the treatment of pulmonary arterial hypertension, with the addition of CMC and device data requested by the FDA. Liquidia initially submitted… Read more . . .
-
A month after regaining rights to PUR1800 and other inhaled narrow spectrum kinase inhibitors from Johnson & Johnson, Pulmatrix has announced that it may also reacquire the rights to its Pulmazole intraconazole DPI (PUR 1900).… Read more . . .
-
Proveris Scientific has announced that it now has the ability to conduct in vitro testing of unit dose nasal drugs in multiple orientations, which is necessary for intranasal products such as opioid overdose reversal drugs,… Read more . . .
-
Inhalation CDMO Vectura has signed an agreement with Inspira Pharmaceuticals to develop an inhaled formulation of a plant extract Inspira is developing for the treatment of COVID-19, the company said. Vectura will create a version of… Read more . . .
-
Oxford Lasers has announced that its Didcot, UK contract services facility has received ISO/IEC 17025:2017 accreditation from the UK Accreditation Service. The company opened the imaging facility for contract testing of aerosol delivery devices in… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of Ryaltris-AZ mometasone furoate / azelastine nasal spray for the treatment of allergic rhinitis in India, touting the low cost of the nasal spray compared to similar products. According to… Read more . . .
-
The FDA has approved a 505(b)(2) NDA for Hikma’s Kloxxado naloxone nasal spray for the reversal of opioid overdose. Hikma says that it expects to launch the nasal spray, which was approved for use in… Read more . . .
-
The organizers of DDL 2021 have announced that the Drug Delivery to the Lungs meeting will once again take place online due to the COVID-19 pandemic, and they have issued a call for papers for… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.